Xenon Pharmaceuticals Yönetim
Yönetim kriter kontrolleri 2/4
Xenon Pharmaceuticals CEO'su Ian Mortimer, Mar2018 tarihinde atandı, in görev süresi 6.67 yıldır. in toplam yıllık tazminatı $ 10.12M olup, şirket hissesi ve opsiyonları dahil olmak üzere 6.6% maaş ve 93.4% ikramiyelerden oluşmaktadır. şirketin hisselerinin 0.06% ine doğrudan sahiptir ve bu hisseler $ 1.90M değerindedir. Yönetim ekibinin ve yönetim kurulunun ortalama görev süresi sırasıyla 4.3 yıl ve 3.7 yıldır.
Anahtar bilgiler
Ian Mortimer
İcra Kurulu Başkanı
US$10.1m
Toplam tazminat
| CEO maaş yüzdesi | 6.6% |
| CEO görev süresi | 6.7yrs |
| CEO sahipliği | 0.06% |
| Yönetim ortalama görev süresi | 4.3yrs |
| Yönetim Kurulu ortalama görev süresi | 3.7yrs |
Son yönetim güncellemeleri
We Think The Compensation For Xenon Pharmaceuticals Inc.'s (NASDAQ:XENE) CEO Looks About Right
May 29
Recent updates
We Think Xenon Pharmaceuticals (NASDAQ:XENE) Can Afford To Drive Business Growth
Oct 20Xenon Pharmaceuticals: Good Data In Epilepsy, But Doubts Remain
Aug 09Is There An Opportunity With Xenon Pharmaceuticals Inc.'s (NASDAQ:XENE) 37% Undervaluation?
Aug 09Xenon Pharmaceuticals (NASDAQ:XENE) Is In A Good Position To Deliver On Growth Plans
Jul 05We Think The Compensation For Xenon Pharmaceuticals Inc.'s (NASDAQ:XENE) CEO Looks About Right
May 29Calculating The Fair Value Of Xenon Pharmaceuticals Inc. (NASDAQ:XENE)
Apr 16Here's Why We're Not Too Worried About Xenon Pharmaceuticals' (NASDAQ:XENE) Cash Burn Situation
Mar 12Xenon Pharmaceuticals: Analysts Still Positive Despite Recent Trial 'Setbacks'
Feb 08Here's Why We're Not Too Worried About Xenon Pharmaceuticals' (NASDAQ:XENE) Cash Burn Situation
Oct 21We Think Xenon Pharmaceuticals (NASDAQ:XENE) Can Afford To Drive Business Growth
Jun 22We're Hopeful That Xenon Pharmaceuticals (NASDAQ:XENE) Will Use Its Cash Wisely
Feb 15We Think Xenon Pharmaceuticals (NASDAQ:XENE) Can Afford To Drive Business Growth
Oct 27Xenon started at outperform at Raymond James on experimental epilepsy drug
Oct 19Xenon Pharmaceuticals Inc. (NASDAQ:XENE) Shares Could Be 31% Below Their Intrinsic Value Estimate
Sep 22Putting Xenon Pharmaceuticals Back In The Spotlight
Sep 06Xenon initiated with Buy at BofA citing potential of anti-seizure drug
Aug 29Xenon Pharmaceuticals Inc.'s (NASDAQ:XENE) Intrinsic Value Is Potentially 67% Above Its Share Price
Jun 13Sizing Up Xenon Pharmaceuticals
Dec 13We're Hopeful That Xenon Pharmaceuticals (NASDAQ:XENE) Will Use Its Cash Wisely
Nov 12We Think Xenon Pharmaceuticals (NASDAQ:XENE) Can Afford To Drive Business Growth
Aug 05Industry Analysts Just Upgraded Their Xenon Pharmaceuticals Inc. (NASDAQ:XENE) Revenue Forecasts By 6.4%
May 13We're Hopeful That Xenon Pharmaceuticals (NASDAQ:XENE) Will Use Its Cash Wisely
Apr 14Is Xenon Pharmaceuticals Inc. (NASDAQ:XENE) Popular Amongst Institutions?
Mar 16CEO Tazminat Analizi
| Tarih | Toplam Tazminat | Maaş | Şirket Kazançları |
|---|---|---|---|
| Jun 30 2024 | n/a | n/a | -US$199m |
| Mar 31 2024 | n/a | n/a | -US$189m |
| Dec 31 2023 | US$10m | US$666k | -US$182m |
| Sep 30 2023 | n/a | n/a | -US$175m |
| Jun 30 2023 | n/a | n/a | -US$165m |
| Mar 31 2023 | n/a | n/a | -US$148m |
| Dec 31 2022 | US$9m | US$595k | -US$126m |
| Sep 30 2022 | n/a | n/a | -US$113m |
| Jun 30 2022 | n/a | n/a | -US$91m |
| Mar 31 2022 | n/a | n/a | -US$83m |
| Dec 31 2021 | US$4m | US$524k | -US$81m |
| Sep 30 2021 | n/a | n/a | -US$66m |
| Jun 30 2021 | n/a | n/a | -US$59m |
| Mar 31 2021 | n/a | n/a | -US$37m |
| Dec 31 2020 | US$2m | US$462k | -US$29m |
| Sep 30 2020 | n/a | n/a | -US$28m |
| Jun 30 2020 | n/a | n/a | -US$28m |
| Mar 31 2020 | n/a | n/a | -US$38m |
| Dec 31 2019 | US$2m | US$421k | -US$42m |
| Sep 30 2019 | n/a | n/a | -US$39m |
| Jun 30 2019 | n/a | n/a | -US$44m |
| Mar 31 2019 | n/a | n/a | -US$42m |
| Dec 31 2018 | US$923k | US$342k | -US$34m |
| Sep 30 2018 | n/a | n/a | -US$34m |
| Jun 30 2018 | n/a | n/a | -US$27m |
| Mar 31 2018 | n/a | n/a | -US$27m |
| Dec 31 2017 | US$945k | US$312k | -US$31m |
Tazminat ve Piyasa: Ian 'nin toplam tazminatı ($USD 10.12M ), US pazarındaki benzer büyüklükteki şirketler için ortalamanın üzerindedir ($USD 6.66M ).
Tazminat ve Kazançlar: Ian şirketinin tazminatı, şirket kârsız olduğu sürece artırıldı.
CEO
Ian Mortimer (48 yo)
6.7yrs
Görev süresi
US$10,117,829
Tazminat
Mr. Ian C. Mortimer, M.B.A, C.P.A, C.M.A., has been the Chief Executive Officer and Director at Xenon Pharmaceuticals Inc. since June 03, 2021. He has been an Independent Director at Perimeter Medical Imag...
Liderlik Ekibi
| İsim | Pozisyon | Görev süresi | Tazminat | Sahiplik |
|---|---|---|---|---|
| President | 6.7yrs | US$10.12m | 0.060% $ 1.9m | |
| Chief Financial Officer | 3.4yrs | US$3.52m | 0% $ 0 | |
| Executive Vice President of Strategy & Innovation | no data | US$2.37m | 0% $ 0 | |
| Chief Commercial Officer | 4.3yrs | US$2.76m | 0.0053% $ 166.8k | |
| Chief Medical Officer | 3.3yrs | US$3.58m | 0% $ 0 | |
| Chief Legal Officer & Corporate Secretary | 2yrs | US$3.55m | Veri yok | |
| Executive Vice President of Human Resources | 5.2yrs | Veri yok | Veri yok | |
| Executive Vice President of Drug Discovery | 8.8yrs | US$545.00k | Veri yok | |
| Executive Vice President of R&D Operations | 4.3yrs | Veri yok | Veri yok |
4.3yrs
Ortalama Görev Süresi
54.5yo
Ortalama Yaş
Deneyimli Yönetim: XENE 'un yönetim ekibi deneyimli olarak değerlendirilmektedir (ortalama görev süresi 4.3 yıldır).
Yönetim Kurulu Üyeleri
| İsim | Pozisyon | Görev süresi | Tazminat | Sahiplik |
|---|---|---|---|---|
| President | 3.4yrs | US$10.12m | 0.060% $ 1.9m | |
| Independent Director | 1.3yrs | US$770.91k | Veri yok | |
| Independent Director | 20.8yrs | US$560.09k | 0.038% $ 1.2m | |
| Independent Director | 4yrs | US$559.58k | 0% $ 0 | |
| Independent Director | 9.5yrs | US$561.42k | 0.0026% $ 83.4k | |
| Independent Chairman | 8.2yrs | US$588.37k | 0.033% $ 1.0m | |
| Independent Director | 1.3yrs | US$770.91k | Veri yok | |
| Independent Director | 3.4yrs | US$548.57k | Veri yok |
3.7yrs
Ortalama Görev Süresi
61.5yo
Ortalama Yaş
Deneyimli Yönetim Kurulu: XENE 'nin yönetim kurulu üyeleri deneyimli olarak kabul edilir (ortalama görev süresi 3.7 yıldır).